Ferro Matteo, Di Lorenzo Giuseppe, Buonerba Carlo, Lucarelli Giuseppe, Russo Giorgio Ivan, Cantiello Francesco, Farhan Abdal Rahman Abu, Di Stasi Savino, Musi Gennaro, Hurle Rodolfo, Vincenzo Serretta, Busetto Gian Maria, De Berardinis Ettore, Perdonà Sisto, Borghesi Marco, Schiavina Riccardo, Almeida Gilberto L, Bove Pierluigi, Lima Estevao, Grimaldi Giovanni, Matei Deliu Victor, Mistretta Francesco Alessandro, Crisan Nicolae, Terracciano Daniela, Paolo Verze, Battaglia Michele, Guazzoni Giorgio, Autorino Riccardo, Morgia Giuseppe, Damiano Rocco, Muto Matteo, Rocca Roberto La, Mirone Vincenzo, de Cobelli Ottavio, Vartolomei Mihai Dorin
Division of Urology, European Institute of Oncology, Milan, Italy.
Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
J Cancer. 2018 Oct 20;9(22):4250-4254. doi: 10.7150/jca.26129. eCollection 2018.
The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p<0.001), multiple tumors (p=0.02), and tumor size larger than 3 cm (p=0.02). Residual HG disease at reTUR was associated with increased preoperative neutrophil-to-lymphocytes ratio (NLR) (p=0.006) and body mass index (BMI)>=25 kg/m. On multivariable analysis, independent predictors for HG residual disease at reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 1.92; 95% CI: 1.32-2.78, p=0.001), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p<0.001) and obesity (OR 2.48; 95% CI: 1.64-3.77, p<0.001). A reTUR in high grade T1 bladder cancer is mandatory as about 25% of patients, presents residual high grade disease. Independent predictors to identify patients at risk of residual high grade disease after a complete TUR include tumor size, presence of carcinoma in situ, and BMI >=25 kg/m.
这项多机构研究的目的是在一大群原发性T1高级别(HG)/3级(G3)膀胱癌患者中,确定再次经尿道切除术(reTUR)时残留高级别疾病的预测因素。对来自13个学术机构的1155例原发性T1 HG/G3膀胱癌患者进行了评估,这些患者在首次经尿道膀胱肿瘤电切术(TUR)后6周内接受了reTUR。进行逻辑回归分析以评估预测因素与reTUR时残留HG的关联。在reTUR时,288例(24.9%)患者发现残留HG癌。出现残留HG癌的患者在首次切除时更有可能存在原位癌(CIS)(p<0.001)、多发肿瘤(p=0.02)和肿瘤大小大于3 cm(p=0.02)。reTUR时残留HG疾病与术前中性粒细胞与淋巴细胞比值(NLR)升高(p=0.006)和体重指数(BMI)>=25 kg/m²有关。多变量分析显示,reTUR时HG残留疾病的独立预测因素为肿瘤大小>3cm(OR = 1.37;95%CI:1.02-1.84,p=0.03)、合并CIS(OR 1.92;95%CI:1.32-2.78,p=0.001)、超重(OR= 2.08;95%CI:1.44-3.01,p<0.001)和肥胖(OR 2.48;95%CI:1.64-3.77,p<0.001)。对于高级别T1膀胱癌患者,reTUR是必需的,因为约25%的患者存在残留高级别疾病。识别完全TUR术后有残留高级别疾病风险患者的独立预测因素包括肿瘤大小、原位癌的存在以及BMI>=25 kg/m² 。